Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung
Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.
Related Articles
Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development
R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer
Nature Cancer – Sears and colleagues found that ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated…
Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
Abstract. Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we…
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
New colorectal cancer screening strategies must advance the standard of care – The Cancer Letter
Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical…
New Developments in CAR T Treatments Webinar Infographic Series
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
Pediatric cancer research cut from spending legislation at last minute Republicans quietly removed hard-won pediatric cancer bills – The Cancer Letter
On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown. To access this subscriber-only content please log in or subscribe.If your…
As fire encroached, City of Hope prepared to evacuate its Duarte campus – The Cancer Letter
On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest. To access…
The current landscape of frontline large B-cell lymphoma trials
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
Combined ODAC documents
Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document
